Make Informed Investment Decisions with Affordable Access to Experts
Making sense of BioMarin's 3 year update on ValRox in Hemophilia patientsTicker(s): BMRN
Name: Dr Guy Young - MD
Institution: University of Southern California
- Director of the Hemostasis and Thrombosis Center at Children’s Hospital Los Angeles, Professor of Pediatrics at USC & Chair of the Scientific and Standardization Committee on Factor VIII, Factor IX, and Rare Bleeding Disorders of the International Society on Thrombosis and Haemostasis.
- Currently manages 320 patients with hemophilia A and B
- Research activities encompass clinical trials in hemophilia, the use of novel anticoagulants in children, and the development of the global hemostasis assays to monitor the effects of medications used to treat bleeding in hemophilia.
What was your impression of the recently updated 3 year patient data for ValRox? LINKAdded By: joe_mccann
More detailed questions to come once community interest is demonstrated!Added By: joe_mccann
How do you view the three year chromogenic factor expression update?
Added By: joe_mccann
Biomarin discussed on the call an internal model that projects the reported three years of expression levels will translate in to 8 years of a durable effect. I believe BioMarin is using non-hemophilia A specific gene therapies to model this forecast - do you put in any weight in to BioMarin projecting out 8 years of durable benefit with the data generated? Would this have any impact on your willingness to prescribe?
What was your general view of the update? Did the update make you incrementally more positive or negative on ValRox?
Biomarin commented that it believes expression levels are plateauing, would you expect the 4 year update to decline or show the plateauing?
What do you make of the median expression continuing to decline but the mean expression somewhat stabilizing? Which measure is more meaningful?
Any other thoughts on the three year update for the phase II high dose?
Added By: joe_mccann
What do you make of the other three year data updates: 96% mean reduction in factor usage and 96% reduction in annualized bleeds?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.